UA99918C2 - 8-бета-замещенные эстратриены как селективно активные эстрогены - Google Patents

8-бета-замещенные эстратриены как селективно активные эстрогены

Info

Publication number
UA99918C2
UA99918C2 UAA201001369A UAA201001369A UA99918C2 UA 99918 C2 UA99918 C2 UA 99918C2 UA A201001369 A UAA201001369 A UA A201001369A UA A201001369 A UAA201001369 A UA A201001369A UA 99918 C2 UA99918 C2 UA 99918C2
Authority
UA
Ukraine
Prior art keywords
selectively active
estrogen receptor
active estrogens
substituted estratrienes
rat
Prior art date
Application number
UAA201001369A
Other languages
English (en)
Ukrainian (uk)
Inventor
Олаф Петерс
Нико Бройер
Ина Тиме
Катя Прелле
Ханс-Петер Мун
Карл-Хайнрих Фритцемайер
Original Assignee
Байер Фарма Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезелльшафт filed Critical Байер Фарма Акциенгезелльшафт
Publication of UA99918C2 publication Critical patent/UA99918C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение касается производных 8β-замещенного эстра-1,3,5(10)-триена общей формулы I, (I)их применение как фармацевтически активных ингредиентов, которые имеют in vitro более высокую афинность в отношении препаратов эстрогенного рецептора из предстательной железы крыс, чем в отношении препаратов эстрогенного рецептора из матки крыс, а также лучшее действие in vivo в яичнике по сравнению с маткой, их получение, их терапевтическое применение и фармацевтических дозированных форм, которые содержат такие новые соединения.
UAA201001369A 2007-07-12 2008-07-11 8-бета-замещенные эстратриены как селективно активные эстрогены UA99918C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (en) 2007-07-12 2007-07-12 8-beta-substituted estratrienes as selectively active estrogens

Publications (1)

Publication Number Publication Date
UA99918C2 true UA99918C2 (ru) 2012-10-25

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201001369A UA99918C2 (ru) 2007-07-12 2008-07-11 8-бета-замещенные эстратриены как селективно активные эстрогены

Country Status (34)

Country Link
US (1) US20090029957A1 (ru)
EP (2) EP2014672A1 (ru)
JP (1) JP2010533152A (ru)
KR (1) KR20100037593A (ru)
CN (1) CN101687902B (ru)
AR (1) AR067507A1 (ru)
AU (1) AU2008274198A1 (ru)
BR (1) BRPI0814207A2 (ru)
CA (1) CA2692727A1 (ru)
CL (1) CL2008002027A1 (ru)
CO (1) CO6270230A2 (ru)
CR (1) CR11211A (ru)
CU (1) CU23885B1 (ru)
CY (1) CY1113351T1 (ru)
DK (1) DK2176282T3 (ru)
DO (1) DOP2010000017A (ru)
EA (1) EA017124B1 (ru)
EC (1) ECSP109872A (ru)
ES (1) ES2393942T3 (ru)
HN (1) HN2010000081A (ru)
HR (1) HRP20120952T1 (ru)
MA (1) MA31565B1 (ru)
NZ (1) NZ582490A (ru)
PA (1) PA8789401A1 (ru)
PE (1) PE20090825A1 (ru)
PL (1) PL2176282T3 (ru)
PT (1) PT2176282E (ru)
RS (1) RS52541B (ru)
SI (1) SI2176282T1 (ru)
TN (1) TN2010000007A1 (ru)
TW (1) TW200911824A (ru)
UA (1) UA99918C2 (ru)
UY (1) UY31220A1 (ru)
WO (1) WO2009007454A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830984C (en) * 2011-03-25 2020-02-11 Universite Laval Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10.
US10744439B2 (en) * 2016-06-24 2020-08-18 K&N Engineering, Inc. Compound air filter and method of removing airborne molecular contaminants and volatile organic compounds therefrom
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
AU2001258341B2 (en) * 2000-04-12 2007-03-15 Schering Aktiengesellschaft 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
EA201000097A1 (ru) 2010-08-30
PA8789401A1 (es) 2009-04-23
TW200911824A (en) 2009-03-16
SI2176282T1 (sl) 2013-02-28
CN101687902B (zh) 2013-07-24
WO2009007454A2 (en) 2009-01-15
EA017124B1 (ru) 2012-10-30
EP2176282B1 (en) 2012-08-22
HRP20120952T1 (hr) 2012-12-31
CA2692727A1 (en) 2009-01-15
NZ582490A (en) 2012-03-30
WO2009007454A3 (en) 2009-03-05
CO6270230A2 (es) 2011-04-20
DK2176282T3 (da) 2012-12-03
JP2010533152A (ja) 2010-10-21
RS52541B (en) 2013-04-30
AR067507A1 (es) 2009-10-14
DOP2010000017A (es) 2010-01-31
CL2008002027A1 (es) 2009-01-16
CU23885B1 (es) 2013-04-19
PE20090825A1 (es) 2009-07-25
ES2393942T3 (es) 2013-01-02
AU2008274198A1 (en) 2009-01-15
EP2014672A1 (en) 2009-01-14
PL2176282T3 (pl) 2013-06-28
MA31565B1 (fr) 2010-08-02
CR11211A (es) 2010-04-27
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
BRPI0814207A2 (pt) 2015-01-27
CY1113351T1 (el) 2016-06-22
UY31220A1 (es) 2009-03-02
PT2176282E (pt) 2012-11-30
ECSP109872A (es) 2010-02-26
HN2010000081A (es) 2013-07-01
EP2176282A2 (en) 2010-04-21
CN101687902A (zh) 2010-03-31
US20090029957A1 (en) 2009-01-29
CU20100008A7 (es) 2011-05-27

Similar Documents

Publication Publication Date Title
DK1272504T3 (da) 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener
IN2012DN04867A (ru)
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
CU24106B1 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
NZ615430A (en) Method for on-demand contraception
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
CO6491067A2 (es) Derivados de 17-hidroxi-17-pentafluoretil-estra-4,9(10)-dien-11arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
UA105920C2 (ru) ПРОИЗВОДНЫЕ СОЕДИНЕНИЙ СТЕРОИДАЛ[3,2-с]ПИРАЗОЛА С ГЛЮКОКОРТИКОИДНОЙ АКТИВНОСТЬЮ
TN2010000007A1 (en) 8-beta- substituted estratrienes as selectively active estrogens
TW200613315A (en) Estradiol prodrugs
MX2008000070A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona.
WO2009059806A3 (en) Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine
RS107004A (en) 9-alpha-substituted estratrienes as selectively active estrogen
JP2011503020A5 (ru)
TW200740778A (en) Non-steroidal progesterone receptor modulators
TH114620A (th) 8-บีตา-ซับสทิทิวเทด เอสทราไทรอีนที่เป็นเอสโทรเจนที่ออกฤทธิ์อย่างมีอำนาจเลือก
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids